The financing was co-led by Amadeus Capital Partners and Manta Ray Ventures to support international expansion and product development.
"This investment allows us to expand our global reach, with sales and support engineering staff in Brazil, the US, India, and grow our Yorkshire headquarters. We will be adding engineers and production workers and moving into a new Sheffield location. The investment will also enable Sitehop to pursue its technology roadmap – fleshing out the range of SAFE products securing all types of data-in-motion, and developing parallel products using our world-class skillsets in cryptography and programmable hardware design. We aim to get Sitehop’s products into the backbone of most of the world’s networks in the next few years."
The funding round was led by XTX Ventures with participation from existing backers including Mercia Ventures and SFC Capital.
"Graide provides transparent, explainable AI, a requirement in today’s world, and can cover all subjects taught from school to university level, saving teacher time. We are pleased to welcome XTX Ventures, which has extensive experience in AI and machine learning, as a new investor in this round."
The financing round was provided by NPIF - Mercia Equity Finance and Mercia funds to support US and European expansion.
"The North West of England has built a strong track record for e-commerce, which stems from its role as a centre for the mail order catalogue industry and the textile trade before that. Pimberly builds on that tradition and is increasingly being recognised as a global leader in its field. The company has been expanding steadily and has created a strong foundation in the US market. This latest investment will help Martin and the team to accelerate its growth and take the business to the next level."
The financing will support the commercial rollout of synthetic affinity reagents and team expansion.
"Securing funding for a novel reagents company in today's investment landscape demonstrates clear confidence in MIP Discovery's technology and renewed commercial strategy. Our proprietary modeling approach to developing synthetic antibody alternatives has already been successful for diagnostic applications, and we have already seen very encouraging traction for our expertise in the cell and gene therapy space."
The funding round was backed by Mercia Ventures, Northstar Ventures, and the North East Venture Fund.
"The support from our investors has allowed us to grow the business to the point where we now work with over 100 customers internationally including large pharma and biotech companies. This latest investment will further enhance our technology and underpin our ability to continue our rapid growth."
